SCRIP
CITELINE COMMERCIAL

18 Jul 2021 |

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: pharma's Q2 prospects; Bayer's plans for the US launch of its CKD drug; big tobacco takes further steps into healthcare; KRAS's emergence in oncology amid ongoing challenges; and tips for European biotech fundraising.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 16 July 2021, including: pharma's Q2 prospects; *Bayer AG*'s plans for the US launch of its CKD drug; big tobacco takes further steps into healthcare; KRAS's emergence in oncology amid ongoing challenges; and tips for European biotech fundraising.

These and all other podcasts are available on the Informa Pharma Intelligence channel on *Apple Podcasts*, *Google Podcasts*, *SoundCloud* and *TuneIn* - and also now on *Spotify Podcasts* - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "*Pharma Is Poised For A COVID-19 Recovery; Will Q2 Deliver?*" - Scrip, 13 Jul, 2021.)
(Also see "*Bayer Focusing On Early CKD Testing In Kerendia US Launch*" - Scrip, 12 Jul, 2021.)
(Also see "*Philip Morris Rebuts 'Cynical' Claims About £1bn Vectura Buy*" - Scrip, 9 Jul, 2021.)
(Also see "*KRAS Inhibitors Show Promise But Long Road Ahead, Say Experts*" - Scrip, 14 Jul, 2021.)
(Also see "*Fundraising Tips From The Top Of European Biotech*" - Scrip, 12 Jul, 2021.)

Click here to explore this interactive content online

© Citeline 2024. All rights reserved.